Premium
Impact of the COVID ‐19 pandemic on biologic treatment in psoriasis patients: A single‐center retrospective study in Japan
Author(s) -
Uchida Hideaki,
Kamata Masahiro,
Egawa Shota,
Nagata Mayumi,
Fukaya Saki,
Hayashi Kotaro,
Fukuyasu Atsuko,
Tanaka Takamitsu,
Ishikawa Takeko,
Ohnishi Takamitsu,
Tada Yayoi
Publication year - 2022
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.16362
Subject(s) - psoriasis , medicine , psoriatic arthritis , pandemic , emergency department , covid-19 , retrospective cohort study , medical record , dermatology , disease , psychiatry , infectious disease (medical specialty)
Abstract The impact of the COVID‐19 pandemic on biologic treatment for psoriasis in Japan remains to be elucidated. This study aimed to investigate changes in biologic treatment and patients' behavior of visiting our department, especially in psoriasis patients treated with biologics before and during the pandemic. Data were collected from medical records retrospectively. The numbers of new psoriasis patients before (2019) and during (2020) the pandemic were compared. Patients' behavior of visiting our department was evaluated. The number of new psoriasis patients who visited our department in 2020 decreased by 35.7% compared with that in 2019. The reduction rate of new patients with psoriasis vulgaris was 49.3%, whereas the numbers of new patients with psoriatic arthritis (PsA) and generalized pustular psoriasis (GPP) were almost the same in 2019 and 2020. The number of patients who newly initiated biologics did not decrease in 2020 compared with that in 2019. As of January 1, 2020, 215 psoriasis patients were treated with biologics. Six patients (2.8%) discontinued biologics treatment possibly due to COVID‐19 in 2020. Among 212 patients with good adherence to visiting our department in the previous year, 24 patients (11.3%) refrained from their visits for at least 1 month. In most cases, refrainment was observed in April and May when the first state of emergency was in effect in Japan. In conclusion, the COVID‐19 pandemic hindered patients from visiting our department. However, its impact on patients who needed intensive care, such as patients with PsA and GPP, and psoriasis patients treated with biologics, was limited.